Characterization of risk factors and efficacy of medical management of immune-related hepatotoxicity in real-world patients with metastatic melanoma treated with immune checkpoint inhibitors-Reference-Cited by-同舟云学术

Characterization of risk factors and efficacy of medical management of immune-related hepatotoxicity in real-world patients with metastatic melanoma treated with immune checkpoint inhibitors

Published:2020-05 Issue: Volume:130 Page:211-218
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Romanski Nicole A.,Holmstroem Rikke B.,Ellebaek Eva,Svane Inge Marie

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference29 articles.

1. Management of metastatic melanoma: improved survival in a national cohort following the approvals of checkpoint blockade immunotherapies and targeted therapies;Dobry;Canc Immun,2018

2. Immunterapi er kræftbehandling med en helt ny bivirkningsprofil;Kondrup;Ugeskrift for Læger,2017

3. Chapter 11 toxicities in immune checkpoint inhibitors, immune checkpoint inhibitors in cancer;Lee,2018

4. Hepatotoxicity of immune checkpoint inhibitors: an evolving picture of risk associated with a vital class of immunotherapy agents;Suzman;Liver Int,2018

5. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the society for immunotherapy of cancer (SITC) toxicity management working group;Puzanov;J Immunother Canc,2017

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hepatobiliary complications of immune checkpoint inhibitors in cancer;Exploration of Targeted Anti-tumor Therapy;2024-07-26

2. Infliximab in steroid-refractory immune-related hepatitis does not demonstrate hepatotoxicity and may shorten time on steroids;Journal for ImmunoTherapy of Cancer;2024-07

3. Neoadjuvant camrelizumab plus apatinib for locally advanced microsatellite instability-high or mismatch repair-deficient colorectal cancer (NEOCAP): a single-arm, open-label, phase 2 study;The Lancet Oncology;2024-07

4. Effect of glucocorticoids for the management of immune-related adverse events on outcome in melanoma patients treated with immunotherapy—a retrospective and biomarker study;Immuno-Oncology and Technology;2024-06

5. Tocilizumab in the treatment of steroid refractory immune-related hepatotoxicity: a case series and review of the literature;Melanoma Research;2024-04-29